Πίσω
Πίσω

18-06-2022

51 K. Kerr - Molecular testing in patients with early stage (I-III) NSCLC, challenges and prospectives

51 K. Kerr - Molecular testing in patients with early stage...

52 P. Christopoulos - The clinical interpertation of NGS

52 P. Christopoulos - The clinical interpertation of NGS

53 N. Normanno - Circulating tumour (ct) DNA in the diagnosis of acquired resistance settings in mNSCLC

53 N. Normanno - Circulating tumour (ct) DNA in the diagnosi...

54 M. Aldea - Diagnostic approaches and challenges in the detection of kinase fusions in NSCLC

54 M. Aldea - Diagnostic approaches and challenges in the de...

55 Discussion

55 Discussion

56 F. Cappuzzo - Setting new horizons with anti-Tigit targeting in lung cancer management

56 F. Cappuzzo - Setting new horizons with anti-Tigit target...

57 C. Kim - Driving the early diagnosis of lung cancer through partnership

57 C. Kim - Driving the early diagnosis of lung cancer throu...

58 M. Karasarides - Maximizing immunotherapy: milestones and future outlook

58 M. Karasarides - Maximizing immunotherapy: milestones and...

60 N. Ahituv - Leveraging sequences missing from the human genome to diagnose lung cancer

60 N. Ahituv - Leveraging sequences missing from the human g...

61 J. Zugazagoitia - Spatial omics for lung cancer biomarker discovery

61 J. Zugazagoitia - Spatial omics for lung cancer biomarker...

62 K. Schalper - Harnessing the tumor microenvironment in NSCLC: beyond PD-L1

62 K. Schalper - Harnessing the tumor microenvironment in NS...

63 N. Arber - CD24: a potential marker for diagnosis and targeting

63 N. Arber - CD24: a potential marker for diagnosis and tar...

64 C. Rolfo - Can liquid biopsy replace tissue?

64 C. Rolfo - Can liquid biopsy replace tissue?

65 E. Felip - Targeting Exon 20 in lung cancer management

65 E. Felip - Targeting Exon 20 in lung cancer management

66 F. Hirsch - Is TMB alive?

66 F. Hirsch - Is TMB alive?